Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase II study of cetuximab monotherapy as first-line treatment in EGFR-expressing metastatic colorectal cancer
2004-001696-19Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Dec 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Confirmed objective response rate. Started Dec 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2004-001696-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001696-19.